On May, 24 BioLineRx Ltd. (BLRX) Analysts See $-0.07 EPS

May 16, 2018 - By Mary Kidd

BioLineRx Ltd. (NASDAQ:BLRX) Corporate Logo

On May, 24. Investors wait BioLineRx Ltd. (NASDAQ:BLRX) to announce its quarterly earnings, as reported by RTT. Analysts expect change of 12.50 % or $0.01 from previous year’s $-0.08 earnings per share compared to current’s $-0.07 earnings per share. 0.00 % EPS growth is what analysts predict. $-0.07 earnings per share was revealed for previous quarter. Ticker’s shares touched $0.8863 during the last trading session after 8.09% change.BioLineRx Ltd. has 1.34M shares volume, 509.36% up from normal. BLRX is downtrending and has moved 24.35% since May 16, 2017. BLRX underperformed the S&P500 by 35.90%.

BioLineRx Ltd. (NASDAQ:BLRX) Ratings Coverage

A total of 2 analysts rate Biolinerx (NASDAQ:BLRX) as follows: 2 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:BLRX) has 9 ratings reports on May 16, 2018 according to StockzIntelligence. The company rating was maintained by Oppenheimer on Tuesday, March 6. On Wednesday, January 17 the rating was maintained by H.C. Wainwright with “Buy”. On Tuesday, March 20 the firm has “Buy” rating given by Oppenheimer. The company rating was maintained by H.C. Wainwright on Tuesday, November 21. On Thursday, December 21 the firm has “Buy” rating by H.C. Wainwright given. On Thursday, December 21 the stock of BioLineRx Ltd. (NASDAQ:BLRX) earned “Buy” rating by Oppenheimer. In Monday, December 4 report H.C. Wainwright maintained it with “Buy” rating and $4.0 target. On Tuesday, March 6 H.C. Wainwright maintained BioLineRx Ltd. (NASDAQ:BLRX) rating. H.C. Wainwright has “Buy” rating and $4.0 target. On Monday, December 4 the stock of BioLineRx Ltd. (NASDAQ:BLRX) has “Buy” rating given by Oppenheimer.

BioLine Rx Ltd, a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs.The firm is valued at $93.94 million. The Company’s development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immunotherapy treatment in development for multiple solid tumors; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions.Currently it has negative earnings. The company's other therapeutic candidates comprise BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction; BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; BL-1210, a drug candidate intended for the treatment of liver fibrosis, primarily non- alcoholic steatohepatitis; BL-1220, an orally administered, novel composition of sodium alginate intended as a novel treatment for various liver failure conditions; and BL-1230, a cannabinoid receptor type 2 intended as a novel anti-inflammatory treatment for dry eye syndrome.

More recent BioLineRx Ltd. (NASDAQ:BLRX) news were released by Benzinga.com, Benzinga.com and Benzinga.com. The first one has “40 Stocks Moving In Wednesday’s Mid-Day Session” as a title and was released on May 16, 2018. The next is “BioLineRx Announces Grant of European Patent Covering Use of BL-8040 with Cytarabine for Treating Acute Myeloid …” on May 16, 2018. And last was released on May 16, 2018, called “Benzinga Pro’s 5 Stocks To Watch Today”.

BioLineRx Ltd. (NASDAQ:BLRX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.